Clinical Trials Logo

Bipolar Disorder Depression clinical trials

View clinical trials related to Bipolar Disorder Depression.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05608135 Recruiting - Major Depression Clinical Trials

AI-based Multi-center Research on Identification/Classification/Aided Diagnosis of Mood Disorder

Start date: December 1, 2022
Phase:
Study type: Observational

At present, diagnosis and recognition of depression and bipolar disorder are mainly based on subjective evidence such as clinical interview and scale evaluation. The corresponding diagnosis basis has some shortcomings, such as poor diagnostic reliability and failure in early identification of bipolar disorder. Therefore, it is of great significance to explore objective diagnostic indicators to remedy the deficiencies. Thereforeļ¼Œthe investigators collect psychological and physiological information data of patients with bipolar disorder and depression.Then the investigators aim to construct and verify the multidimensional emotion recognition model to analyze the personality characteristics, negative emotions and cognitive reactions of different individuals, and form a systematic accurate recognition and evaluation tool.

NCT ID: NCT04211961 Recruiting - Clinical trials for Bipolar Disorder Depression

Scopolamine in Bipolar Depression

SCOPE-BD
Start date: March 23, 2021
Phase: Phase 2
Study type: Interventional

This is a single-site, randomised, double-blind, placebo-controlled, parallel, phase IIb clinical trial. The primary objective of the SCOPE-BD study is to investigate the efficacy and safety of IV Scopolamine, compared to placebo, in reducing severity of depression in individuals with bipolar disorder who are experiencing a depressive episode of at least moderate severity

NCT ID: NCT03598868 Recruiting - Clinical trials for Bipolar Disorder Depression

Vortioxetine add-on Treatment Improves the Symptoms in Patients With Bipolar Depression

ViBiD
Start date: August 8, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to validate the efficacy of Vortioxetine augmentation in bipolar disorder patients with depressive symptoms.